Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 7 to 11, 2022. This […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 7 to 11, 2022. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
FDA Postpones Decision on Pfizer COVID-19 Vaccine for Under 5s
FRIDAY, Feb. 11, 2022 (HealthDay News) — The U.S. Food and Drug Administration announced Friday that it will postpone an advisory panel meeting that was slated for next week to weigh the Pfizer COVID-19 vaccine for use in young children.
FDA Approves New Antibody Drug to Fight Omicron Variant
FRIDAY, Feb. 11, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Friday gave the nod for a new monoclonal antibody treatment that works against the omicron variant.
Mandatory COVID-19 Tests Lifted for Vaccinated Travelers to Britain
FRIDAY, Feb. 11, 2022 (HealthDay News) — Vaccinated travelers will no longer have to take COVID-19 tests when they enter Britain, officials announced Friday.
U.S. Buys 600,000 Doses of New COVID-19 Treatment Still Awaiting FDA Approval
FRIDAY, Feb. 11, 2022 (HealthDay News) — The U.S. government has bought 600,000 doses of a new antibody drug called bebtelovimab that seems able to beat back the omicron variant, even though the medication has yet to be given the green light by the U.S. Food and Drug Administration. The company said the contract is worth at least $720 million.
Prior SARS-CoV-2 Infection Less Protective Against Omicron Variant
FRIDAY, Feb. 11, 2022 (HealthDay News) — Previous severe acute respiratory syndrome coronavirus 2 infection is about 90 percent effective for preventing reinfection with the alpha, beta, and delta variants but offers lower protection against reinfection with the omicron variant, according to a letter to the editor published online Feb. 9 in the New England Journal of Medicine.
New Symptoms, Conditions May Develop After Positive Test for SARS-CoV-2
FRIDAY, Feb. 11, 2022 (HealthDay News) — The prevalence of certain symptoms and conditions is increased at 31 to 150 days following testing among individuals who test positive versus negative for severe acute respiratory syndrome coronavirus 2, according to a study published online Feb. 3 in JAMA Network Open.
New York State Lifts Indoor Mask Mandate
THURSDAY, Feb. 10, 2022 (HealthDay News) — An indoor mask mandate in New York state will end on Thursday, but masks will still be required in schools and for everyone using public transit.
Test-to-Stay Program Safe for Facilitating In-Person Learning
THURSDAY, Feb. 10, 2022 (HealthDay News) — A statewide test-to-stay program involving daily rapid antigen testing is safe and can maximize in-person learning during the pandemic, according to a study published online Feb. 8 in Pediatrics.
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
Most U.S. Adults Unsure Which Vaccines CDC Recommends During Pregnancy .jpg)
Pregnancy Complications Rare for Women Receiving CAR T-Cell Therapy 
Higher Parental Vitamin B12 Tied to Lower Prevalence of Birth Defects 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
